Tingrex coated tablets 10 mg. №30


Alzheimer’s disease from mild to severe. Medications for dementia.



Composition and form of release
The main active ingredient is memantine.
The drug is marketed in tablet form, 10 mg memantine in 1 tablet.
Pharmacological properties
This drug belongs to a group of drugs that are used to treat dementia.
The active substance is memantine. It is an adamantane derivative, a substance that is chemically and physically close to amantadine. It is also a potential-dependent moderate affinity non-competitive NMDA receptor antagonist. Able to modulate the effects of glutamate (capable of causing neuronal dysfunction) at its increased tonic level. In the progression of dementia, glutamatergic neurotransmission involving NMDA receptors plays an essential role.
Possesses a high degree of bioavailability – up to 100% during the peak period, which is reached in the period from 3 to 8 hours after ingestion. The effectiveness does not depend on the food intake.
The specified pharmaceutical agent is used for the treatment of Alzheimer’s disease of all forms of severity – from mild to severe.
Also used for vascular or mixed dementia of all forms of severity.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
It is used with caution in patients with epilepsy or a tendency to muscle cramps.
Do not use concomitantly with NMDA antagonists such as amantadine, ketamine or dextromethorphan.
Application during pregnancy and lactation
The drug should not be administered during pregnancy.
If there is a need to use this drug during lactation, breastfeeding should be suspended for this period.
Method of administration and dosage
The drug Tingrex is used orally, once a day, regardless of food intake.
Treatment is carried out under the supervision of a physician and under the supervision of a person who will look after the patient.
Recommended dosages:

  • 1 week – 5 mg daily;
  • 2 weeks – 10 mg daily;
  • 3 weeks – 15 mg daily;
  • Week 4 – 20 mg daily is also the recommended maintenance dosage.

Elderly patients over 65 years of age and patients with liver disease do not need dosage adjustment.
With kidney disease, the dosage needs to be reduced.
Treatment continues until the drug is beneficial and produces no noticeable side effects.
The dosage adjustment of the duration of treatment is determined individually by the attending physician.
Overdose (200 mg memantine for 3 consecutive days) can cause side effects such as:

  • weakness;
  • fatigue;
  • diarrhea.

Reactions from the central nervous system are also possible, such as blurred consciousness, hypersomnia, drowsiness, dizziness, agitation, aggression, gait disturbances.
Treatment is symptomatic. There is no specific antidote.
Recommended gastric lavage, intake of enterosorbents, forced diuresis.
Side effects
Side effects may occur during treatment with this drug. In particular, there may be:

  • nausea, diarrhea, vomiting, colitis, dyspepsia, itching, allergic urticaria, other manifestations of allergic reactions;
  • mycotic infections;
  • drowsiness, hallucinations, psychosis;
  • dizziness, convulsions, gait disturbances;
  • arterial hypertension, venous thrombosis, thromboembolism, heart failure;
  • dyspnea;
  • constipation, vomiting, pancreatitis;
  • hepatitis;
  • headache, asthenia.
  • others.

Storage conditions and periods
The shelf life is no more than 3 years.
Does not need special storage conditions.